Trial Profile
A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Proof of concept; Therapeutic Use
- Acronyms LINC-1; LINC-2
- Sponsors Novartis Pharmaceuticals
- 18 Jun 2023 Results (n=229) of a pooled analysis assessing how dosing, including dose uptitration and adjustments during long-term maintenance, can provide rapid, sustained mUFC control, minimize AEs and improve treatment outcomes from LINC program trials (LINC 2, 3 and 4) presented at the 105th Annual Meeting of the Endocrine Society
- 23 Mar 2021 Results (n=19) reporting long-term efficacy and safety results of LINC 2 study following an optional extension (n=16) presented at the 103rd Annual Meeting of the Endocrine Society
- 16 Dec 2019 Status changed from active, no longer recruiting to completed.